A Phase 1 interventional study of Efsubaglutide Alfa Injection and Placebo in Diabete Type 2, sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.. Withdrawn at 1 site in Brazil. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment
PK bridging has been exempted
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil — 35 open to participants now, 44 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Brazil.
Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, this one is the 290th largest by enrollment of the 295 interventional ones that give a count, is one of 23 that started in 2026, is one of 7 in phase 1, and was the 302nd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →35 of the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Sao Francisco · Sites in Brazil
Ages 40–80 · Healthy volunteers
Eli Lilly and Company · Sites in Brazil, United States, Argentina and 8 more countries
Ages 18+
AstraZeneca · Sites in Brazil, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 13 more countries
Ages 45+
Novo Nordisk A/S · Sites in Brazil, United States, Argentina and 7 more countries
Ages 10–18
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
317 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 151 · Phase 4 37
First in 2002; this study’s year is marked. 23 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 329 across the 295 interventional studies, 370 across the 22 observational. Of the 239 that completed or were terminated, 116 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 317 have an industry lead sponsor. The 10 most frequent:
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. has 7 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
5 of the studies in Diabetes Mellitus, Type 2 with a site in Brazil that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT07463859University of Sao PauloEffects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabetes Mellitus | 2027-01-31 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
| NCT06735859Federal University of São PauloEating Window and Sleep Disorders on Glycemic Control, Cardiovascular Risk, and Weight Loss | 2027-06 |
| NCT07846319epHealthEvaluation of the Effectiveness of Implementing a Screening Strategy for the Diagnosis of Prediabetes and Type 2 Diabetes Mellitus in Primary Health Care in a Brazilian Municipality | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 317 studies in Diabetes Mellitus, Type 2 with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, randomized, double-blind, placebo-controlled, single-dose study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of YN-011. Participants will be randomized to receive a single subcutaneous dose of YN-011 1 mg, YN-011 3 mg, or matching placebo. The study includes screening, approximately 2 days of study-site confinement from the day before dosing to 24 hours after dosing, and outpatient follow-up for 4 weeks. Assessments include safety monitoring, PK blood sampling, PD evaluations, and immunogenicity testing.
This is a Phase I, randomized, double-blind, placebo-controlled, single-dose, parallel-group study in healthy adult participants in Brazil to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of YN-011 following subcutaneous administration.
The study will be conducted at a single clinical study site in Brazil and will enroll approximately 48 healthy adult participants. Participants will be randomized into 2 dose cohorts, a 1 mg cohort and a 3 mg cohort. Within each cohort, participants will be randomized in a 5:1 ratio to receive a single subcutaneous dose of YN-011 or matching placebo. Overall, the study will include 3 treatment groups: YN-011 1 mg, YN-011 3 mg, and placebo. The placebo will be matched in appearance and administered using the same device format in order to maintain blinding.
The main objectives of the study are to assess the safety and tolerability of YN-011 after single-dose administration in healthy adult participants, to characterize its PK profile, to evaluate selected PD effects, and to assess immunogenicity. Safety evaluations will include adverse events, clinical laboratory tests, vital signs, electrocardiograms, physical examinations, and other appropriate clinical assessments. PK assessments will characterize the concentration-time profile of YN-011 after dosing. PD assessments will evaluate the biologic effects of YN-011 after administration. Immunogenicity assessments will evaluate whether participants develop an immune response to YN-011.
The study includes a screening period of up to 4 weeks, a study-site confinement period of approximately 2 days, and an outpatient follow-up period of 4 weeks, for a maximum total study duration of approximately 8 weeks per participant. Participants will be admitted to the clinical study site on the day before dosing and will undergo pre-dose assessments to confirm continued eligibility. On Day 1, participants will receive a single subcutaneous injection of YN-011 1 mg, YN-011 3 mg, or matching placebo in the abdomen using a prefilled auto-injector.
During the confinement period, participants will remain under close clinical observation and will receive a controlled diet with specified fasting and fluid intake restrictions around dosing. After completion of the post-dose confinement period, participants will be discharged from the clinical study site and will return for scheduled outpatient follow-up visits for PK blood sampling, safety monitoring, PD evaluations, and immunogenicity assessments.
The results of this study are expected to provide clinical information on the safety, PK, PD, and immunogenicity profile of single-dose YN-011 in healthy adult participants in Brazil.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Previously or currently diagnosed diabetes mellitus (T1D or T2D) or prediabetes, according to the diagnostic criteria of the Brazilian Diabetes Society (SBD) guideline, defined by any of the following laboratory findings:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Efsubaglutide Alfa Injection
Drug: Efsubaglutide Alfa Injection
Drug: Placebo
Efsubaglutide alfa will be administered as a single subcutaneous injection at a dose of 1 mg or 3 mg on Day 1 in healthy adult participants. The study drug will be administered in the abdomen using a prefilled auto-injector.
Matching placebo will be administered as a single subcutaneous injection on Day 1 in healthy adult participants. Placebo is identical in appearance and presentation to efsubaglutide alfa and will be administered in the abdomen using a matching prefilled auto-injector.
Concentration (Cmax) of YN-011 maximum Observed Plasma
Time frame: Predose through Day 29
Concentration (Tmax) of YN-011 Time to Maximum Observed Plasma
Time frame: Predose through Day 29
Concentration (AUC0-t) of YN-011 Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable
Time frame: Predose through Day 29
Concentration of Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of YN-011
Time frame: Predose through Day 29
Terminal Elimination Half-Life (t1/2) of YN-011
Time frame: Predose through Day 29
Rate of Incidence and severity of adverse events
Incidence and severity of adverse events, including treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs).
Time frame: From informed consent through Day 29
Rate of Clinically significant changes in vital signs, clinical laboratory tests, and 12-lead electrocardiograms
Clinically significant changes in vital signs, clinical laboratory tests, including hematology, biochemistry, amylase, lipase, and urinalysis, and 12-lead electrocardiograms.
Time frame: Baseline through Day 29
Change rate of from baseline in fasting plasma glucose
Time frame: Baseline through Day 29
Change Rate of From Baseline in Body Weight
Time frame: Baseline through Day 29
Incidence rate of anti-drug antibodies and neutralizing antibodies
Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs), if ADA positive.
Time frame: Baseline through Day 29
Correlation Between AUC0-inf of YN-011 and Change From Baseline in Fasting Plasma Glucose at Day 29
Time frame: Baseline and Day 29
Correlation between AUC0-inf of YN-011 and change from baseline in body weight at Day 29
Time frame: Baseline and Day 29
Comparison of AUC0-inf of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
Comparison of AUC0-inf of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.
Time frame: Predose through Day 29
Comparison of AUC0-t of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
Comparison of AUC0-t of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.
Time frame: Predose through Day 29
Comparison of Cmax of YN-011 Between Healthy Adult Brazilian Participants and Chinese Phase I Healthy Participants
Comparison of Cmax of YN-011 between healthy adult Brazilian participants in this study and existing healthy-participant data from the Chinese Phase I clinical program.
Time frame: Predose through Day 29
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Aug 2026, 2 months later.
How these figures are worked out, and which studies are left out of them.
PK bridging has been exempted
PK bridging has been exempted
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Efsubaglutide alfa
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.